News

US nod for Novartis' skin cancer pill Odomzo


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

US nod for Novartis' skin cancer pill Odomzo

Date: 28/07/2015


The US Food and Drug Administration has approved Novartis’ once-daily pill Odomzo for locally advanced basal cell carcinoma that has returned following surgery or radiation therapy, or for patients unable to have these interventions.

BCC consists of abnormal, uncontrolled growths or lesions that arise in the skin's basal cells, which line the deepest layer of the epidermis, and accounts for more than 80% of non-melanoma skin cancers.

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019